These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 19025433)

  • 41. Exercise ventilation inefficiency in heart failure: pathophysiological and clinical significance.
    Tumminello G; Guazzi M; Lancellotti P; Piérard LA
    Eur Heart J; 2007 Mar; 28(6):673-8. PubMed ID: 17124197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pulmonary hypertension in left heart disease].
    Opitz CF; Gläser S; Ewert R
    Dtsch Med Wochenschr; 2009 Aug; 134 Suppl 5():S167-9. PubMed ID: 19718607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beta-blockers and heart failure in older people.
    Le Couteur DG; Bailey L; Naganathan V
    Eur Heart J; 2006 Apr; 27(7):887-8; author reply 888-9. PubMed ID: 16478748
    [No Abstract]   [Full Text] [Related]  

  • 44. Mode of death in patients with systolic heart failure.
    Patel J; Heywood JT
    J Cardiovasc Pharmacol Ther; 2007 Jun; 12(2):127-36. PubMed ID: 17562783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New inotropic drugs for treatment of congestive heart failure.
    Schwertz DW; Piano MR
    Cardiovasc Nurs; 1990; 26(2):7-12; discussion 12. PubMed ID: 1969769
    [No Abstract]   [Full Text] [Related]  

  • 46. Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure.
    Schmitz W; Boknik P; Linck B; Müller FU
    Mol Cell Biochem; 1996 Apr 12-26; 157(1-2):251-8. PubMed ID: 8739255
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beta blockade in diabetic heart failure.
    Lukas MA
    Heart Fail Clin; 2006 Jan; 2(1):89-99. PubMed ID: 17386880
    [No Abstract]   [Full Text] [Related]  

  • 48. Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry).
    Piccini JP; Hranitzky PM; Kilaru R; Rouleau JL; White HD; Aylward PE; Van de Werf F; Solomon SD; Califf RM; Velazquez EJ
    Am J Cardiol; 2008 Dec; 102(11):1427-32. PubMed ID: 19026290
    [TBL] [Abstract][Full Text] [Related]  

  • 49. beta-Blocker therapy for congestive heart failure: clinical considerations.
    Kamath SA; Yancy CW
    Postgrad Med; 2005 Dec; 118(6 Suppl Beta-Blockers):12-20. PubMed ID: 19667706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strategies to attenuate pathological remodeling in heart failure.
    Eapen Z; Rogers JG
    Curr Opin Cardiol; 2009 May; 24(3):223-9. PubMed ID: 19318933
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
    Botha P; Parry G; Dark JH; Macgowan GA
    J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Clinico-pharmacologic aspects of cardioactive drugs].
    Erdmann E; Schwinger RH; Böhm M
    Klin Anasthesiol Intensivther; 1995; 47():46-60. PubMed ID: 7715179
    [No Abstract]   [Full Text] [Related]  

  • 53. Optimal management of chronic heart failure in patients with chronic kidney disease.
    Zachariah D; Kalra PA; Kalra PR
    J Ren Care; 2009 Mar; 35(1):2-10. PubMed ID: 19200271
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inotropes and beta-blockers: is there a need for new guidelines?
    Bristow MR; Shakar SF; Linseman JV; Lowes BD
    J Card Fail; 2001 Jun; 7(2 Suppl 1):8-12. PubMed ID: 11605160
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cardioprotection with beta-blockers: myths, facts and Pascal's wager.
    Messerli FH; Bangalore S; Yao SS; Steinberg JS
    J Intern Med; 2009 Sep; 266(3):232-41. PubMed ID: 19702791
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beta-blocker therapy for patients with ventricular heart failure and reduced systolic function.
    Giles TD
    Postgrad Med; 2003 Dec; 114(6 Suppl Role):18-29. PubMed ID: 19667666
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacogenetics and response to beta-adrenergic receptor antagonists in heart failure.
    Muszkat M; Stein CM
    Clin Pharmacol Ther; 2005 Mar; 77(3):123-6. PubMed ID: 15735606
    [No Abstract]   [Full Text] [Related]  

  • 58. Phosphodiesterase inhibitors.
    Br J Hosp Med; 1989 Sep; 42(3):238. PubMed ID: 2790366
    [No Abstract]   [Full Text] [Related]  

  • 59. [Pulmonary arterial hypertension. Part II: Medical and surgical treatment].
    Manes A; Marinelli A; Palazzini M; Negro L; Leci E; Gambetti S; Bachetti C; Beciani E; Conficoni E; Branzi A; Galiè N
    G Ital Cardiol (Rome); 2009 Jun; 10(6):366-81. PubMed ID: 19603608
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Heart failure: a state of brain natriuretic peptide deficiency or resistance or both!
    Chen HH
    J Am Coll Cardiol; 2007 Mar; 49(10):1089-91. PubMed ID: 17349889
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.